|
1
|
Dy GK, Hillman SL, Rowland KM Jr, Molina
JR, Steen PD, Wender DB, Nair S, Mandrekar S, Schild SE and Adjei
AA: North Central Cancer Treatment Group Study N0326: A front-line
window of opportunity phase 2 study of sorafenib in patients with
advanced nonsmall cell lung cancer: North Central Cancer Treatment
Group Study N0326. Cancer. 116:5686–5693. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cabibbo G and Craxi A: Epidemiology, risk
factors and surveillance of hepatocellular carcinoma. Eur Rev Med
Pharmacol Sci. 14:352–355. 2010.PubMed/NCBI
|
|
3
|
Peng L, Zhou Y, Ye X and Zhao Q:
Treatment-related fatigue with everolimus and temsirolimus in
patients with cancer - a meta-analysis of clinical trials. Tumour
Biol. 36:643–654. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S,
Kim JS, Luo R, Feng J, Ye S, Yang TS, et al: Efficacy and safety of
sorafenib in patients in the Asia-Pacific region with advanced
hepatocellular carcinoma: A phase III randomised, double-blind,
placebo-controlled trial. Lancet Oncol. 10:25–34. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cucchetti A, Piscaglia F, Cescon M, Serra
C, Colecchia A, Maroni L, Venerandi L, Ercolani G and Pinna AD: An
explorative data-analysis to support the choice between hepatic
resection and radiofrequency ablation in the treatment of
hepatocellular carcinoma. Dig Liver Dis. 46:257–263. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhai B and Sun XY: Mechanisms of
resistance to sorafenib and the corresponding strategies in
hepatocellular carcinoma. World J Hepatol. 5:345–352. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhao X, Tian C, Puszyk WM, Ogunwobi OO,
Cao M, Wang T, Cabrera R, Nelson DR and Liu C: OPA1 downregulation
is involved in sorafenib-induced apoptosis in hepatocellular
carcinoma. Lab Invest. 93:8–19. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
European Association For The Study Of The
Liver; European Organisation For Research and Treatment of Cancer:
EASL-EORTC clinical practice guidelines: Management of
hepatocellular carcinoma. J Hepatol. 56:908–943. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gravante G, Overton J, Sorge R, Bhardwaj
N, Metcalfe MS, Lloyd DM and Dennison AR: Radiofrequency ablation
versus resection for liver tumours: An evidence-based approach to
retrospective comparative studies. J Gastrointest Surg. 15:378–387.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bruix J and Sherman M: American
Association for the Study of Liver Diseases: Management of
hepatocellular carcinoma: An update. Hepatology. 53:1020–1022.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bhardwaj N, Strickland AD, Ahmad F,
El-Abassy M, Morgan B, Robertson GS and Lloyd DM: Microwave
ablation for unresectable hepatic tumours: Clinical results using a
novel microwave probe and generator. Eur J Surg Oncol. 36:264–268.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sherman M, Burak K, Maroun J, Metrakos P,
Knox JJ, Myers RP, Guindi M, Porter G, Kachura JR, Rasuli P, et al:
Multidisciplinary Canadian consensus recommendations for the
management and treatment of hepatocellular carcinoma. Curr Oncol.
18:228–240. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yim HJ, Suh SJ and Um SH: Current
management of hepatocellular carcinoma: An Eastern perspective.
World J Gastroenterol. 21:3826–3842. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ma H, Zhang Y, Wang Q, Li Y, He J, Wang H,
Sun J, Pan K, Chen M and Xia J: Therapeutic safety and effects of
adjuvant autologous RetroNectin activated killer cell immunotherapy
for patients with primary hepatocellular carcinoma after
radiofrequency ablation. Cancer Biol Ther. 9:903–907. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Karabulut K, Aucejo F, Akyildiz HY,
Siperstein A and Berber E: Resection and radiofrequency ablation in
the treatment of hepatocellular carcinoma: A single-center
experience. Surg Endosc. 26:990–997. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Birsen O, Aliyev S, Aksoy E, Taskin HE,
Akyuz M, Karabulut K, Siperstein A and Berber E: A critical
analysis of postoperative morbidity and mortality after
laparoscopic radiofrequency ablation of liver tumors. Ann Surg
Oncol. 21:1834–1840. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Muallem N and Solomon SB: Advances in
interventional oncology: Percutaneous therapies. Curr Radiol Rep.
2:522014. View Article : Google Scholar
|
|
18
|
Morimoto N, Isoda N, Watanabe S, Otake T,
Hirosawa T, Tsukui M, Miyata N, Murayama K, Iwashita C, Takaoka Y,
et al: A case of small hepatocellular carcinoma treated with
laparoscopic multipolar radiofrequency ablation with a no-touch
ablation procedure. Clin J Gastroenterol. 7:510–515. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tsuji K, Yamazaki H, Nagai K, Matsui T,
Tomonari A, Kang J, Sakurai Y, Kodama Y and Maguchi H: A case of
laparoscopic radiofrequency ablation therapy using bipolar RFA
system for hepatocellular carcinoma. Kanzo. 54:819–825. 2013.
View Article : Google Scholar
|
|
20
|
Kawamura Y, Ikeda K, Fukushima T, Hara T,
Hosaka T, Kobayashi M, Saitoh S, Sezaki H, Akuta N, Suzuki F, et
al: Potential of a no-touch pincer ablation procedure for small
hepatocellular carcinoma that uses a multipolar radiofrequency
ablation system: An experimental animal study. Hepatol Res.
44:1234–1240. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Forner A, Reig ME, de Lope CR and Bruix J:
Current strategy for staging and treatment: The BCLC update and
future prospects. Semin Liver Dis. 30:61–74. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Soerjomataram I, Lortet-Tieulent J, Parkin
DM, Ferlay J, Mathers C, Forman D and Bray F: Global burden of
cancer in 2008: A systematic analysis of disability-adjusted
life-years in 12 world regions. Lancet. 380:1840–1850. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li L, Zhang J, Liu X, Li X, Jiao B and
Kang T: Clinical outcomes of radiofrequency ablation and surgical
resection for small hepatocellular carcinoma: A meta-analysis. J
Gastroenterol Hepatol. 27:51–58. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kharaziha P, De Raeve H, Fristedt C, Li Q,
Gruber A, Johnsson P, Kokaraki G, Panzar M, Laane E, Osterborg A,
Zhivotovsky B, Jernberg-Wiklund H, Grander D, Celsing F, Bjorkholm
M, Vanderkerken K and Panaretakis T: Sorafenib has potent antitumor
activity against multiple myeloma in vitro, ex vivo, and in vivo in
the 5T33MM mouse model. Cancer Res. 72:5348–5362. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tamaskar I, Garcia JA, Elson P, Wood L,
Mekhail T, Dreicer R, Rini BI and Bukowski RM: Antitumor effects of
sunitinib or sorafenib in patients with metastatic renal cell
carcinoma who received prior antiangiogenic therapy. J Urol.
179:81–86. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Waghray A, Balci B, El-Gazzaz G, Kim R,
Pelley R, Narayanan MK, Estfan B, Romero-Marrero C and Aucejo F:
Safety and efficacy of sorafenib for the treatment of recurrent
hepatocellular carcinoma after liver transplantation. CLIN
TRANSPLANT. 2013.27:555–561. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hong SN, Lee SY, Choi MS, Lee JH, Koh KC,
Paik SW, Yoo BC, Rhee JC, Choi D, Lim HK, et al: Comparing the
outcomes of radiofrequency ablation and surgery in patients with a
single small hepatocellular carcinoma and well-preserved hepatic
function. J Clin Gastroenterol. 39:247–252. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ikeda K, Kobayashi M, Saitoh S, Someya T,
Hosaka T, Sezaki H, Suzuki Y, Suzuki F, Akuta N and Arase Y:
Cost-effectiveness of radiofrequency ablation and surgical therapy
for small hepatocellular carcinoma of 3cm or less in diameter.
Hepatol Res. 33:241–249. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Feng X, Xu R, Du X, Dou K, Qin X, Xu J,
Jia W, Wang Z, Zhao H, Yang S, Guo C, Liu T and Ma K: Combination
therapy with sorafenib and radiofrequency ablation for BCLC Stage
0-B1 hepatocellular carcinoma: A multicenter retrospective cohort
study. Am J Gastroenterol. 109:1891–1899. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Berretta M, Di Francia R and Tirelli U:
Sorafenib combined with percutaneous radiofrequency ablation for
the treatment of medium-sized hepatocellular carcinoma. Eur Rev Med
Pharmacol Sci. 19:2521–2522. 2015.PubMed/NCBI
|
